Chaudhary, Sanjib
Appadurai, Muthamil Iniyan
Maurya, Shailendra Kumar
Nallasamy, Palanisamy
Marimuthu, Saravanakumar
Shah, Ashu
Atri, Pranita
Ramakanth, Chirravuri Venkata
Lele, Subodh M.
Seshacharyulu, Parthasarathy
Ponnusamy, Moorthy P.
Nasser, Mohd W.
Ganti, Apar Kishor
Batra, Surinder K.
Lakshmanan, Imayavaramban
Funding for this research was provided by:
Moorthy P Ponnusamy (R01 CA210637)
Apar K Ganti (I01 BX004676/BX/BLRD)
Surinder K Batra (P01 CA217798)
Article History
Received: 7 June 2022
Accepted: 1 March 2023
First Online: 14 March 2023
Declarations
:
: The mouse studies were performed in accordance with the US Public Health Service ‘Guidelines for the Care and Use of Laboratory Animals’ under an approved protocol by the Institutional Animal Care and Use Committee, University of Nebraska Medical Center.
: Not applicable.
: SKB is the co-founder of Sanguine Diagnostics and Therapeutics, Inc. AKG has served as a consultant for AstraZeneca, Flagship Biosciences, G1 Therapeutics, Jazz Pharmaceuticals, Cardinal Health, Mirati Therapeutics, Beigene Ltd, Sanofi Genzyme, Blueprint Medicines, Regeneron Pharmaceuticals; has received research support from Takeda and Oncoceutics; and has served as a DSMC Chair for YmAbs Therapeutics. None of the other authors has any conflict of interest. The authors declare that there are no competing interests.